Merrimack Pharmaceuticals (MACK) Files $172.5M IPO

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is $172.5 million. Merrimack plans to list on the Nasdaq Global Market under the ticker "MACK."

The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SEC Issues Guidance to Tokenize Stocks After Clarity Act Failure, Robinhood (HOOD) Gains
• BofA Securities Upgrades HawkEye 360 Inc (HAWK) to Buy, 'Attractive valuation flying below the radar'
• CoreWeave plans $3B convertible notes offering due 2033